SXTP
60 Degrees Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
60 Degrees Pharmaceuticals has 6 disclosed suppliers and 1 disclosed customer in SEC filings.
Largest filed tie
92.00%
of SXTP revenue · Undisclosed U.S. pharmaceutical distributor
—
—
SentenceFor the year ended December 31, 2025 , our U.S. pharmaceutical distributor accounted for 92 % of our total net product sales and Kodatef sales to our Australian distributor accounted for 6 % of total net product sales ( 95 % and 5 % for the year ended December 31, 2024 , respectively).
basisSXTP FY2025 revenue $1M
SXTP 10-Kaccession 0001554855-26-000467
SentenceAfter deduction of a 5% administrative fee by FSURF, capped at $15,000 annually, and reimbursement of patent prosecution expenses, we will receive 20% of license income and FSURF will receive 80% of license income.
SXTP 10-Kaccession 0001554855-26-000467
Sentencewe entered into the Exclusive License Agreement (the "2014 NUS-SHS Agreement") with National University of Singapore ("NUS") and Singapore Health Services Pte Ltd ("SHS") in which we were granted a license from NUS and SHS with respect to their share of patent rights regarding "Dosing Regimen for Use of Celgosivir as an Antiviral Therapeutic for Dengue Virus Infection" to develop, market and sell licensed products.
SXTP 10-Kaccession 0001554855-26-000467
Sentencewe entered into the Exclusive License Agreement (the "2014 NUS-SHS Agreement") with National University of Singapore ("NUS") and Singapore Health Services Pte Ltd ("SHS") in which we were granted a license from NUS and SHS with respect to their share of patent rights regarding "Dosing Regimen for Use of Celgosivir as an Antiviral Therapeutic for Dengue Virus Infection" to develop, market and sell licensed products.
SXTP 10-Kaccession 0001554855-26-000467
Sentencethe Company must make royalty payments equal to 4 % of Net Sales (as defined in the Tufts MC Agreement) of tafenoquine products sold in a format labeled for use in the treatment of babesiosis or 2 % of Net Sales of tafenoquine products sold in a format not labeled for use in the treatment of babesiosis.
SXTP 10-Kaccession 0001554855-26-000467
SentenceWe entered into a cooperative research and development agreement with the United States Army in 2014 to complete development of Arakoda for prevention of malaria.
SXTP 10-Kaccession 0001554855-26-000467
SentenceIn exchange for the license granted to Yale to us, we agreed to pay Yale a royalty of 2% on net sales of licensed products covering the licensed patents if the licensed produce it branded for treatment of babesiosis and a royalty of 1% on net sales if licensed products covering the licensed product is not specifically branded for treatment of babesiosis.
SXTP 10-Kaccession 0001554855-26-000467
60 Degrees Pharmaceuticals, Inc.
0.94
−0.01 · −0.84%
post 0.94 0.00%
+51.50%
shares held · 5 largest managers
Expected move
No implied move.